Q-MOL L.L.C. In Silico Pharmaceuticals

Please contact our primary consultant directly:

Dr. Anton Cheltsov                anton@q-mol.com                   (619) 796-3070

Q-MOL VLS was successfully used to discover allosteric inhibitors of matrix metalloproteinase MT1-MMP hemopexin domain.  Only 19 ligands were screened in vitro and in cell-based assay to identify a small molecule inhibiting tumor growth in an animal model.

Cancer Res. 2012 May 1;72(9):2339-49. Epub 2012 Mar 9.

Q-MOL protein-ligand docking technology was successfully employed to identify a novel class of allosteric inhibitors of viral two-component processing proteases from West Nile and Dengue viruses.  Paper reprint here.

NEW! Cloud-based computational web services are available at q-mol.org

The distribution version of the software is NOT yet available.